Search
Meropenem
go.drugbank.com/drugs/DB00760ApprovedInvestigationalThe treatment aims to resolve infection-related symptoms and achieve negative urine culture, where the infections are proven or strongly suspected to be caused by susceptible bacteria. … Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall components, which leads to cell death.
Synonyms: (4R,5S,6S)-3-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]thio}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acidProducts: MEROZAN 1 G ENJEKTABL TOZ İÇEREN FLAKON, 10 ADET, MEROSID 500 MG IV ENJEKTABL TOZ ICEREN 1 FLAKONChlorpropamide
go.drugbank.com/drugs/DB00672ApprovedWithdrawnIt belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. … Up to 80% of the single oral dose of chlorpropramide is metabolized, likely in the liver; 80-90% of the dose is excreted in urine as unchanged drug and metabolites.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesProducts: ORBİN 250 MG TABLET, 100 ADET, ORBIN 250 MG TABLET, 1000 ADETNifedipine
go.drugbank.com/drugs/DB01115ApprovedInvestigationalNifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine]. … [A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.
Mixtures: NIF TEN 50, NIFETEX-TR CAPSULECategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 InducersLenograstim
go.drugbank.com/drugs/DB13144ApprovedWithdrawnLenograstim is a recombinant granulocyte colony-stimulating factor used as an immunostimulating agent.
Synonyms: G-CSF (CHO cell derived), Glycosylated recombinant G-CSFProducts: กราโนไซด์ ชนิดฉีด 100 MCG, กราโนไซด์ ชนิดฉีด 250 MCGErenumab
go.drugbank.com/drugs/DB14039ApprovedInvestigationalErenumab (AMG-334) (INN; trade name Aimovig) is a human monoclonal antibody designed specifically to bind and antagonize the calcitonin gene-related peptide receptor (CGRPR) as a means to prevent migraines … It is composed of 2 heavy chains, each containing 456 amino acids, and 2 light chains of the lambda subclass, each containing 216 amino acids, with an approximate molecular weight of 150 kDa [FDA Label
Products: PASURTA® 140 MG /ML, AIMOVIG (140 MG/ML SOLUTION FOR INJECTION)Nivolumab
go.drugbank.com/drugs/DB09035ApprovedInvestigational[A35203] It was developed by Bristol Myers Squibb.[L12129] Nivolumab was granted FDA approval on 22 December 2014.
Categories: Immunoglobulin GProducts: OPDIVO CONCENTRATE FOR SOLUTION FOR INFUSION 10 MG/ML, OPDIVO 100 INF. IÇIN KONS. IÇEREN FLAKON, 1 ADETGlucosamine
go.drugbank.com/drugs/DB01296Approved[A231894,A232289] It is currently not approved as a prescription product by the FDA, but is widely available over the counter. … [A232289] Treatment with chondroprotective drugs, such as glucosamine sulfate may offer additional benefits to nonsteroidal anti-inflammatory drugs treating the painful symptoms of OA.
Mixtures: DONA PLUS 750 MG + 600 MG SAŞE, 60 ADET, GLUCOSAMINE & CHONDROITIN 500/400 MGProducts: DONA 750 MG FİLM KAPLI TABLET, 180 ADET, DONA 750 MG FİLM KAPLI TABLET, 60 ADETMometasone
go.drugbank.com/drugs/DB00764ApprovedInvestigationalMometasone is a corticosteroid not currently used in medical products. Mometasone furoate however, is still in use.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersProducts: AIRMETA 200 MCG INHALASYON ICIN TOZ ICEREN BLISTER, 60 DOZ, AIRMETA 400 MCG INHALASYON ICIN TOZ ICEREN BLISTER, 60 DOZNalbuphine
go.drugbank.com/drugs/DB00844ApprovedInvestigationalIt appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: Nubain 10 mg/ml Injektionslösung, NALBUFINA CLORHIDRATO 10 MG/ML.Von Willebrand factor human
go.drugbank.com/drugs/DB13133ApprovedInvestigationalThe human vWF is used to manage and control bleeding episodes in patients with von Willebrand disease and hemophilia A. It was first approved by the FDA in 2015. … [A32262] Exogenous sources of vWF are used to restore functional levels of vWF in blood disorders associated with deficient or abnormal blood clotting.
Mixtures: BIOSTATE FOR INJECTION 50 iu/ml, IMMUNATE 1000 IU/750 IU IV INFUZYONLUK TOZ ICEREN FLAKON, 1 ADETProducts: IMMUNATE 100 IU/ML POWDER AND SOLVENT FOR SOLUTION FOR INJECTION, IMMUNATE 50 IU/ML POWDER AND SOLVENT FOR SOLUTION FOR INJECTION